Retail chatter around WW International surged Tuesday after the company’s expanded collaboration with Novo Nordisk officially ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Novo Nordisk is likely to draw investor attention on Monday after the company said it is moving forward with the oral and ...

Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to ...

Glucagon-like peptide-1 (GLP-1) injections such as Wegovy (semaglutide) and Zepbound (tirzepatide) are the most effective weight-loss medications available today. Oral GLP-1 pills, such as ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ... or Wegovy, 1.7 milligrams or 2.4 milligrams.

In a late-stage clinical trial, Wegovy (semaglutide) significantly reduced liver inflammation and reversed scarring in people with the liver disease MASH. MASH is associated with obesity and type ...

Novo Nordisk CEO Lars Fruergaard Jørgensen is stepping down, the Wegovy-maker said Friday, citing recent market challenges. The Danish pharmaceutical giant said Fruergaard Jørgensen would remain ...

The weight loss drug Wegovy treated a serious form of liver disease in about two-thirds of patients in a major clinical trial, according to the findings published Wednesday in the New England ...

Stream Connecticut News for free, 24/7, wherever you are. Novo Nordisk said Friday that CEO Lars Fruergaard Jørgensen is stepping down as the Wegovy-maker seeks to revive its ailing fortunes amid ...

Novo Nordisk's Rybelsus, a daily pill with the same properties as Ozempic, was FDA-approved for diabetes in 2019. However, its weight loss results didn't stack up to other GLP-1 drugs in studies ...